Issued: Tuesday 07 February 2012, London UK GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders

2011 underlying sales +4% (reported -3%) EPS before major restructuring* 114.1p Total dividends of 75p

Download GSK Q4 results 2011 as a PDF

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.